Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration       Hotel       Presenter Instructions       Support & Exhibits     2014 Overview       Program       Faculty     Travel & Transportation      

Quick Links
Abstract Submission

General Information
     Call for Abstracts
     Abstract Deadline
     No-Show Policy
Responsibilities of Abstract Presenters
     Responsibilities of Abstract

     Presenters

     Author Disclosure
     Publication & Embargo

     Regulations

     No-Show Policy

     Permission to Reproduce

     Presentation

Abstract Preparation
     Abstract Subject Categories
     Preparation
     Submission
Abstract Submission
     Submission
     Corrections
     Submission Fee
     Review Decision
     Scholarships

Call for Abstracts   >  Abstract Preparation

 
Spacer

Abstract Subject Categories

The subject categories for abstract submission are listed below. You must select the most appropriate category for your abstract and insert its corresponding number in the box on the abstract form. Please be aware that the Symposium Abstract Review Committee may re-categorize your abstract if doing so is deemed appropriate.

Subject Categories List

DETECTION/DIAGNOSIS

Axillary Nodes
101. Axillary Staging and Sentinel Nodes
Pathology

102. Diagnostic Pathology
103. Biopsy Techniques

104. Circulating Markers

105. Circulating Tumor Cells

106. Micrometastases

Imaging and Screening

107. Breast Imaging - Mammography
108. Breast Imaging - MRI

109. Breast Imaging - Other Methods
110. Molecular, Functional, and Novel Imaging
111. Radiology - Tumor Monitoring

112. Screening

Other

113. Detection/Diagnosis - Other

TUMOR CELL AND MOLECULAR BIOLOGY
201. Angiogenesis
202. Animal Models
203. Apoptosis and Senescence

204. Biomarkers

205. Cell Cycle Regulation

206. Cellular Mechanisms

207. DNA Damage and Repair

208. Drug Resistance

209. Endocrine Therapy and Resistance

210. Epigenetics

211. Epithelial-Mesenchymal Transition

212. Etiology/Carcinogenesis

213. Gene Therapy

214. Genetics - Germline Changes

215. Genetics - Somatic Changes

216. Genomics

217. Growth Factors

218. Hormonal Factors and Receptors

219. Immunology and Preclinical Immunotherapy

220. Mammary Development and Differentiation

221. Metabolism and Breast Cancer

222. Microenvironment - Stromal - Epithelial Interactions

223. MicroRNAs

224. Molecular Profiles

225. New Drugs and Machanisms

226. Novel/Emerging Therapeutic Targets

227. Oncogenes/Tumor Suppressor Genes

228. Stem/Progenitor Cells

229. Systems Biology of Breast Cancer

230. Telomeres/Telomerase

231. Tumor Heterogeneity/Molecular Subclassification

232. Tumor Progression, Invasion, and Metastasis

233. Virology

234. Tumor Cell and Molecular Biology - Other

PROGNOSTIC AND PREDICTIVE FACTORS
301. Prognostic Factors - Preclinical

302. Prognostic Factors - Clinical Testing and Validation

303. Response Predictions - Biomarkers and Other Factors

304. Prognostic Factors and Biomarkers - Methods

305. Prognostic and Predictive Factors - Other

EPIDEMIOLOGY, RISK, AND PREVENTION

401. Epidemiology - Population Studies

402. Epidemiology - Genetic and Molecular
403. Ethnic/Racial Aspects
404. Familial Breast Cancer - Genetic Testing

405. Familial Breast Cancer - Molecular Genetics

406. Prevention - Behavioral Interventions

407. Prevention - Nutritional Studies

408. Prevention - Clinical Trials

409. Prevention - Preclinical Studies and Model Systems

410. Risk Factors and Modeling

411. Epidemiology, Risk, and Prevention - Other

PSYCHOSOCIAL, QUALITY OF LIFE, AND EDUCATIONAL ASPECTS

Social and Education Issues

501. Advocacy
502. Cost-Effectiveness

503. Disparities and Barriers to Care

504. Doctor-Patient Communication

505. Education

Quality of Life Issues

506. Palliation and Pain Management

507. Psychosocial Aspects

508. Quality of Life - Supportive Care

509. Survivorship Research

Other

510. Psychosocial, QOL, and Educational Aspects - Other

TREATMENT

Adjuvant Therapy
601. Adjuvant Chemotherapy

602. Adjuvant Endocrine Therapy

603. Adjuvant Therapy - Targeted

604. Adjuvant Therapy - Other

Advanced Disease Treatment

605. Advanced Chemotherapy

606. Advanced Endocrine Therapy

607. Advanced Therapy - Targeted

608. Advanced Therapy - Other

Surgery and Radiotherapy

609. Breast Conservation

610. Radiotherapy

611. Surgery

612. Reconstruction

Therapeutic Strategies

613. Neoadjuvant Chemotherapy

614. Neoadjuvant Endocrine Therapy

616. Antiangiogenic Therapy (Adjuvant and Metastatic)

617. Antibody-Based Regimens

619. HER2-Targeted Therapy

620. Immunotherapy (Clinical)

621. New Drugs and Treatment Strategies

622. Novel Targets and Targeted Agents

623. Signal Transduction Inhibitors

624. Toxicities - Management

Types and Sites of Breast Cancer

625. Bone Metastases

626. Brain Metastases

627. DCIS/LCIS

628. Male Breast Cancer

629. Inflammatory Breast Cancer

Research Resources

630. Patient Resources

631. Tissue and Data Banks

632. Clinical Trials Design and Management

Other

633. Treatment - Other

 

ONGOING CLINICAL TRIALS

701. Ongoing Clinical Trials (see rules below)

 

This category is for work that is ongoing. It is to inform and inspire, and/or to invite the collaboration of others. It is to not to discuss the trial results, either preliminary or formally completed - presentations with this type of information should be submitted as regular abstracts. 

Trials with any type of focus may be submitted (treatment, prevention, biomarker endpoints, supportive care, educational, and psychosocial endpoints). 

What should be presented in the abstract and eventually in the poster is: 

  • A brief background discussion.
  • Trial design
  • Eligibility criteria
  • Specific aims
  • Statistical methods
  • Present accrual and target accrual
  • Contact information for people with a specific interest in the trial

Again, inclusion of preliminary or final trial results will disqualify an abstract in this category and is not allowed on the poster, though information on accrual to date or confirmation of feasibility is acceptable. 

 

Poster presentations in the Ongoing Clinical Trials category are not subject to SABCS pre-publication and embargo policies.

Top
 
Spacer


Preparation

  • Abstract must be submitted online.
  • The abstract must be in English.
  • There is no limit to the number of abstracts submitted.
  • There is no limit to the number of authors listed on an abstract.
  • Any author who, for religious reasons, cannot present on a particular day of the week, must provide

that information by email to c4asupport@coetruman.com.

  • Submitting an abstract online does not register you to attend the Symposium.  You can register
    for the Symposium by clicking here.

 

 
Top
 
Spacer

Submission
  • When finished with your online submission, be sure to click the "Submit" button.  Abstracts received without a properly completed Disclosure will not be considered.  The size limit for the abstract (including title, body, tables and spaces) is 3400 characters.  Please see the submissions website for specific details regarding tables.
  • Abstracts are due by 11:59 CDT on June 10, 2014.
Top
 
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Presenter Instructions | Support & Exhibits | 2014 Overview | Program | Faculty | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy